TRT advice from telehealth vs. gym bros: what the science says

What did @rodgardner87 actually say?

The core claim here is that TRT is not a lifetime commitment, and that the fear of permanent shutdown is based on outdated thinking. He says "once I start, I can never stop" is the primary misconception, and credits adjunct therapies, specifically what he calls "Encoma Fiend" (enclomiphene), HCG, Clomid, and DHEA, for preserving testicular function while on testosterone. His clinic, Dynamic3, apparently co-prescribes enclomiphene with TRT from the start. The framing is reassuring and sales-oriented: don't be afraid, we've got a solution, book an appointment. That combination of genuine medical nuance and aggressive promotional energy is exactly why this video needs unpacking.

Does the science back this up?

Partially, yes. The concern that exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis is real and well-documented. Testosterone signals the hypothalamus and pituitary to reduce LH and FSH output, which drives testicular atrophy and suppresses endogenous production. That part is not a myth invented by nervous gym bros. However, the creator is correct that this suppression is not necessarily permanent. Recovery is possible, and adjunct therapies can help.

A 2013 study by Ramasamy et al. in the Journal of Urology found that HCG co-administration during TRT maintained intratesticular testosterone and spermatogenesis, supporting the idea that testicular function can be preserved. Enclomiphene, a selective estrogen receptor modulator, works by blocking estrogen's negative feedback on the pituitary, prompting it to keep producing LH and FSH despite exogenous testosterone. Studies like Wiehle et al. (2014, Andrology) showed enclomiphene raised LH, FSH, and testosterone while preserving sperm parameters. These are legitimate tools. The problem is how they were described here.

What did they get wrong (or right)?

He got the concept directionally right but the execution is sloppy in ways that matter clinically. DHEA is lumped in with HCG and enclomiphene as if it plays a comparable role in preserving HPG axis function. It does not. DHEA is a precursor hormone with weak evidence and a completely different mechanism. Grouping it with agents that directly stimulate gonadotropin output is misleading.

More importantly, the claim that co-prescribing enclomiphene guarantees you "have not damaged your natural testosterone function" is overstated. Recovery after TRT discontinuation is not universal. A 2020 review by Crosnoe-Shipley et al. in Therapeutic Advances in Urology noted that recovery timelines after TRT cessation vary widely, and some men, particularly those on long-term therapy or with pre-existing HPG dysfunction, do not fully recover. Saying the game is simply "take care of your testicular function" with an add-on prescription glosses over real individual variability and the fact that none of these adjuncts are FDA-approved for this specific co-administration purpose in TRT protocols.

Credit where it is due: the general message that reversibility is possible, and that preservation strategies exist, is clinically grounded and pushes back on a real source of patient anxiety.

What should you actually know?

If you are considering TRT and worried about permanent suppression, that concern is legitimate but not a foregone conclusion. The HPG axis can recover after TRT discontinuation, especially when cessation is managed carefully. Adjunct therapies like HCG and enclomiphene have genuine evidence supporting their use in preserving spermatogenesis and testicular volume during TRT. The evidence for clomiphene as a standalone TRT alternative is also real, though it is off-label.

But "you will be fine if you just take our add-on" is not a guarantee any honest clinician should make. Recovery depends on duration of TRT use, baseline HPG function, age, and individual variation. A 2022 paper by Samplaski et al. in Fertility and Sterility found that men who used testosterone for fertility-relevant reasons had variable and sometimes prolonged recovery after stopping, even with HCG-based restart protocols.

• Ask any prescribing clinician what their specific protocol is for discontinuation support, not just for starting.
• DHEA is not in the same category as HCG or enclomiphene for HPG preservation. Do not treat them as equivalent.
• Enclomiphene is not FDA-approved as a co-administration agent in TRT. Its use in this context is off-label.
• Compounded versions of any of these agents are not equivalent to branded formulations in terms of regulatory oversight.